Trial · NCT05093296
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder
NCT05093296, Phase 2, Phase 3, Completed, Central Institute of Mental Health, Mannheim
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder. Trials, record NCT05093296. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05093296
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder
- NCT number
- NCT05093296
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 62 participants, actual
- Lead sponsor
- Central Institute of Mental Health, Mannheim
- Conditions
- Alcohol Use Disorder, Alcoholism, Alcohol Addiction
- Interventions
- Oxytocin nasal spray, Naltrexone Pill, Placebo
- First posted
- 2021-10-26
- Last updated
- 2024-03-29
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Alcohol Urge Questionnaire (AUQ) | 60 minutes after oxytocin/placebo application and directly after the combined stress- and cue-exposure will serve as primary outcome measure at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Alcohol Urge Questionnaire (AUQ) | 35 minutes after oxytocin/placebo application at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Alcohol Urge Questionnaire (AUQ) | 70 minutes after oxytocin/placebo application at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Alcohol Urge Questionnaire (AUQ) | 80 minutes after oxytocin/placebo application at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Alcohol Urge Questionnaire (AUQ) | 90 minutes after oxytocin/placebo application at Visit 3 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Alcohol Urge Questionnaire (AUQ) | 85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4 | Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ |
| Secondary | Primary Appraisal secondary Appraisal Scale (PASA) | 35 minutes after oxytocin/placebo application at Visit 3 | Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
| Secondary | Primary Appraisal secondary Appraisal Scale (PASA) | 60 minutes after oxytocin/placebo application at Visit 3 | Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
| Secondary | Primary Appraisal secondary Appraisal Scale (PASA) | 90 minutes after oxytocin/placebo application at Visit 3 | Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
| Secondary | Primary Appraisal secondary Appraisal Scale (PASA) | 85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4 | Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35410938 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Food Cue Reactivity Task | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05093296
GET https://conductscience.org/api/trials/v1/NCT05093296/registered?page=2